Fujino N, Haga Y, Sakamoto K, Egami H, Kimura M, Nishimura R, Akagi M
Jpn J Clin Oncol. 1986 Dec;16(4):335-46.
Serum levels of CA15-3, a mammary tumor associated antigen recognized by two different murine monoclonal antibodies (115D8 and DF3), were investigated in patients with mammary carcinoma and other benign or malignant diseases. The reference value of the serum CA15-3 level was obtained as 24 units/ml at the 99% confidence limit among healthy individuals (n = 462). Elevation of serum CA15-3 levels was observed in 24.3% of overall patients with mammary carcinoma. Serum CA15-3 levels in breast cancer patients correlated with the clinical stage; higher percentages of positivity were observed in those with advanced breast cancer (stage IV, 64.7%, recurrent, 52.4% and metastatic, 70.3%). Furthermore, elevated serum CA15-3 levels in breast cancer patients responded well to the effect of therapy. Although the serum CA15-3 test gave percentages of positivity of breast cancer similar to those found by the serum CEA test, the serum CA15-3 test revealed lower percentages of positivity than the serum CEA test among patients with benign breast lesions, liver cirrhosis or other carcinomas. These results suggest that the serum CA15-3 antigen level provides a very useful marker for diagnosis and clinical monitoring of patients with breast cancer.
研究了两种不同鼠单克隆抗体（115D8和DF3）识别的乳腺肿瘤相关抗原CA15-3在乳腺癌及其他良性或恶性疾病患者中的血清水平。在健康个体（n = 462）中，血清CA15-3水平的参考值在99%置信限下为24单位/毫升。在所有乳腺癌患者中，24.3%观察到血清CA15-3水平升高。乳腺癌患者的血清CA15-3水平与临床分期相关；晚期乳腺癌患者（IV期，64.7%，复发，52.4%，转移，70.3%）的阳性率更高。此外，乳腺癌患者血清CA15-3水平升高对治疗效果反应良好。虽然血清CA15-3检测得到的乳腺癌阳性率与血清CEA检测相似，但在乳腺良性病变、肝硬化或其他癌症患者中，血清CA15-3检测的阳性率低于血清CEA检测。这些结果表明，血清CA15-3抗原水平为乳腺癌患者的诊断和临床监测提供了一个非常有用 的标志物。
